Industry News

- Read more about Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center Collaborate as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program
Bristol-Myers Squibb Company (NYSE:BMY) announced that they have entered into a collaboration agreement with The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM research program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
- Read more about Mylan receive U.S. FTC Approval For Proposed Acquisition Of Perrigo
Mylan N.V. (NASDAQ: MYL) announced the U.S. Federal Trade Commission ("FTC") has cleared the company's proposed transaction to acquire Perrigo Company plc (NYSE: PRGO; TASE) subject to Mylan's divestiture of certain products following the consummation of the offer. The FTC clearance represents the final regulatory clearance needed by Mylan to close its acquisition of Perrigo and represents the last remaining condition that needs to be satisfied for the successful completion of the offer other than the acceptance condition.
- Read more about European Commission Approves Bayer Flupyradifurone
Bayer CropScience has reached an important milestone towards the market introduction of its innovative insecticide Sivanto Prime in Europe. Its active ingredient flupyradifurone, which belongs to the chemical class of butenolides, has been approved for the maximum time span of 10 years by the European Commission in accordance with Regulation (EC) 1107/2009. The first national registrations of Sivanto prime in European countries are expected in 2016 and the market introduction is planned for 2017.
- Read more about Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound
Boehringer Ingelheim announced at the BIO-Europe® conference in Munich, Germany, the initiation of a global Phase II trial evaluating the efficacy and safety of BI 1482694 (HM61713) in patients with T790M mutation-positive non-small cell lung cancer (NSCLC), whose tumours stopped responding to currently available epidermal growth factor receptor (EGFR) directed therapies. The primary endpoint of this trial, which is the first in a broad clinical development programme for BI 1482694, is objective response rate (ORR).

[adsense:336x280:8701650588]
- Read more about Maggi will be back this month, all tests cleared
Nestle India said the "masala" version of Maggi noodles will hit the retail shelves as early as this month, having cleared all the tests ordered by the Bombay High Court at three accredited laboratories.
- Read more about Biocon is the Only Asian Company to be Ranked in Top 20 Global Biotech Employers for 2015
(BWI); Biocon Ltd has earned the distinction of being the only Asian Biopharma Company to feature among the top biotechnology employers in the world as ranked by Science magazine. The ranking is a result of a global survey conducted by the American Association for the Advancement of Science (AAAS) through its affiliate Science magazine to determine which companies in the biotech and pharmaceutical industry have the best reputations as employers globally.
- Read more about Anand Diagnostic Laboratory Inaugurates Pioneering Drive-Through Blood Collection Service in Bangalore
(BWI); Anand Diagnostic Lab, one of India‘s oldest and leading, stand-alone diagnostic services company, launched a new drive-through blood collection service that will help customers reduce the time and effort required to give samples for required tests.
- Read more about Sanofi and BioNTech Declare Cancer immunotherapy collaboration and license agreement
Sanofi and BioNTech announced that they have entered into a multiyear exclusive collaboration and license agreement. This research collaboration between Sanofi and BioNTech will leverage the scientific expertise of the two organizations to discover and develop up to five cancer immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs).
- Read more about Valeant Pharmaceuticals Cuts Ties to Philidor RX
Valeant Pharmaceuticals informed that it was cutting ties with mail-order pharmacy Philidor RX, which will shut down operations as soon as possible.

[adsense:336x280:8701650588]
- Read more about Glenmark Pharma receives tentative US FDA approval for lacosamide tablets
Glenmark Pharmaceuticals Inc USA (Glenmark), has been granted tentative approval by the United States Food & Drug Administration (FDA) for its lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat tablets, 50 mg, 100 mg, 150 mg and 200 mg of UCB Inc.